Skip to main navigation
Skip to Content
Overview
News & Events
News Releases
Events & Presentations
Governance
Governance Overview
Executive Leadership
Board of Directors
Committee Composition
Stock Information
Stock Quote & Chart
Historic Price Lookup
Investment Calculator
Analyst Coverage
Financials
SEC Filings
Resources
Investor FAQs
Email Alerts
Contact IR
Search
Your selection
Clear all
2024
Remove
Filter by content type
SEC filing
(27)
News
(8)
Event
(3)
Asset
(1)
Filter by content year
(-)
2024
(39)
Filter by form group
Filter by category
Filter by type
Filter by category
Filter by category
Filter by category
Search
News
Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG348 in Patients with BRCA1/2-Mutant and Other HRD+ Cancers
News
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News
Tango Therapeutics to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
Event
Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
SEC Filings
Form 8-K
SEC Filings
Form 4
SEC Filings
Form 4
SEC Filings
Form 4
SEC Filings
Form 4
News
Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2024
Pagination
Page 1
Next page
››
Print
RSS Feeds
Email Alerts
Contact IR